Aspira Women’s Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch
AUSTIN, Texas, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS) rate setting process, the Centers for Medicare & Medicaid Services (CMS) has proposed to crosswalk the fee paid to the company for OvaWatch to the fee paid historically for Ova1. If finalized later this month (as was preliminarily approved in September), Aspira would be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning in January 2024. The public comment period ended on October 27.
- If finalized later this month (as was preliminarily approved in September), Aspira would be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning in January 2024.
- “Crosswalking” refers to a process for setting the Medicare reimbursement rate for a new laboratory test by assigning the new code the same rate as a comparable existing test.
- Aspira supports the proposal to crosswalk OvaWatch to Ova1 and believes it is appropriate given the similarity of pre-analytical, analytical, and post-analytical characteristics of the two assays.
- “We are one step closer to achieving our mission of ensuring this ground-breaking technology is available to all women when they are facing an ovarian cancer diagnosis.”